Intravenous Artesunate

About this approach

Artesunate is a medicine derived from the artemisinin drug family and is used intravenously for severe malaria. Researchers have also investigated whether it could have a role against cancer. The established malaria indication does not demonstrate that cancer infusions are effective or equally safe. Intravenous artesunate is also different from drinking Artemisia tea or taking an herbal supplement. Cancer use requires a careful discussion of the limited clinical evidence, possible toxicity and available research protocols.

Where it fits: Investigational anticancer use of an antimalarial medicine

Where this treatment is used

A phase I intravenous artesunate study in people with advanced solid tumors primarily examined tolerability and dose-limiting effects. It reported no objective tumor responses; some participants had stable disease. Later treatment decisions need evidence for the exact cancer and combination being proposed. Approval or routine use for severe malaria is a separate matter from validation as an oncology treatment.

Procedure and practical considerations

The early cancer study reported serious effects including neutropenic fever, allergic reactions, abnormal liver tests and significant nausea or vomiting. Delayed breakdown of red blood cells has been reported after artesunate treatment for malaria; the setting and risk cannot simply be assumed identical in cancer patients. Blood counts, liver function and medication interactions need clinical review. A fever, breathing difficulty or marked weakness during an investigational infusion program requires prompt medical assessment.

Clinics reporting this approach

These clinic profiles mention this approach in their published materials. Open a profile to compare locations, services, practical details, and ways to get started.